Cryoport: Strong Pipeline Of Cell And Gene Therapy Approvals (NASDAQ:CYRX)
· seekingalpha.com
Cryoport returned to EBITDA profitability in 2Q26, with strong Life Science Services growth and positive operating cash flow. Learn why CYRX stock is a buy.
Cryoport, Inc. ( CYRX ) rated BUY has seen its share price increase by 82% YTD. The stock is supported by a strong pipeline for cell and gene therapy commercial...